Takeda Pharmaceutical Co (Takeda Pharmaceutical Co) Minority Interest : $4.67 Mil (As of Dec. 2023)

View and export this data going back to 2009. Start your Free Trial

What is Takeda Pharmaceutical Co Minority Interest?

Minority interest is the carrying amount of the equity interests owned by non-controlling shareholders, partners, or other equity holders in one or more of the entities included in the reporting entity's consolidated financial statements.

Takeda Pharmaceutical Co's minority interest for the quarter that ended in Dec. 2023 was $4.67 Mil.

Takeda Pharmaceutical Co Minority Interest Historical Data

The historical data trend for Takeda Pharmaceutical Co's Minority Interest can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Takeda Pharmaceutical Co Minority Interest Chart

Takeda Pharmaceutical Co Annual Data

Trend

Mar14

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Minority Interest

Get a 7-Day Free Trial

36.04

37.18

38.09

4.25

4.11

Takeda Pharmaceutical Co Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Minority Interest	Get a 7-Day Free Trial															3.85	4.11	4.37	4.55	4.67

Takeda Pharmaceutical Co Minority Interest Calculation

Takeda Pharmaceutical Co (Takeda Pharmaceutical Co) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Takeda Pharmaceutical Co Ltd (OTCPK:TKPHF) » Definitions » Minority Interest

Comparable Companies

Traded in Other Exchanges

TAK:USA TAK:Mexico 4502:Japan TKD:Germany TAKP34:Brazil

Address

1-1, Nihonbashi-Honcho 2-Chome, Chuo-ku, Tokyo, JPN, 103-8668

Website

https://www.takeda.com

Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 4 trillion in fiscal 2022. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with 50% derived from the U.S., 20% from Japan, 20% from Europe and Canada.